Cargando…

Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African “meningitis belt”. In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung Hye, Pezzoli, Lorenzo, Yacouba, Harouna, Coulibaly, Tiekoura, Djingarey, Mamoudou H., Perea, William A., Wierzba, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/
https://www.ncbi.nlm.nih.gov/pubmed/22276104
http://dx.doi.org/10.1371/journal.pone.0029116
_version_ 1782221767133102080
author Kim, Sung Hye
Pezzoli, Lorenzo
Yacouba, Harouna
Coulibaly, Tiekoura
Djingarey, Mamoudou H.
Perea, William A.
Wierzba, Thomas F.
author_facet Kim, Sung Hye
Pezzoli, Lorenzo
Yacouba, Harouna
Coulibaly, Tiekoura
Djingarey, Mamoudou H.
Perea, William A.
Wierzba, Thomas F.
author_sort Kim, Sung Hye
collection PubMed
description MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African “meningitis belt”. In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1–14/15–29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6–70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7–91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1–77.0) by card and 93.4% (95% CI: 91.0–95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15–29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.
format Online
Article
Text
id pubmed-3262782
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32627822012-01-24 Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010 Kim, Sung Hye Pezzoli, Lorenzo Yacouba, Harouna Coulibaly, Tiekoura Djingarey, Mamoudou H. Perea, William A. Wierzba, Thomas F. PLoS One Research Article MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African “meningitis belt”. In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1–14/15–29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6–70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7–91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1–77.0) by card and 93.4% (95% CI: 91.0–95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15–29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population. Public Library of Science 2012-01-20 /pmc/articles/PMC3262782/ /pubmed/22276104 http://dx.doi.org/10.1371/journal.pone.0029116 Text en Kim et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kim, Sung Hye
Pezzoli, Lorenzo
Yacouba, Harouna
Coulibaly, Tiekoura
Djingarey, Mamoudou H.
Perea, William A.
Wierzba, Thomas F.
Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title_full Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title_fullStr Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title_full_unstemmed Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title_short Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010
title_sort whom and where are we not vaccinating? coverage after the introduction of a new conjugate vaccine against group a meningococcus in niger in 2010
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/
https://www.ncbi.nlm.nih.gov/pubmed/22276104
http://dx.doi.org/10.1371/journal.pone.0029116
work_keys_str_mv AT kimsunghye whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT pezzolilorenzo whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT yacoubaharouna whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT coulibalytiekoura whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT djingareymamoudouh whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT pereawilliama whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010
AT wierzbathomasf whomandwherearewenotvaccinatingcoverageaftertheintroductionofanewconjugatevaccineagainstgroupameningococcusinnigerin2010